Takeda's zasocitinib shows strong efficacy in psoriasis trials

Takeda's zasocitinib met all primary and ranked secondary endpoints in two pivotal phase 3 studies for moderate-to-severe plaque psoriasis. Over half of participants achieved clear or almost clear skin (PASI 90), with approximately 30% achieving completely clear skin (PASI 100) by week 16. The studies showed superiority over placebo for sPGA 0/1 and PASI 75 at week 16, with PASI 75 response rates increasing through week 24.

Zasocitinib demonstrated a safety profile consistent with previous clinical studies and was generally well-tolerated. The company plans to submit a new drug application to the FDA and other regulatory authorities starting in fiscal year 2026. This marks Takeda's third positive phase 3 readout this year, with zasocitinib, oveporexton, and rusfertide showing potential for future growth.